Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Cabaletta Bio stock
Own Cabaletta Bio stock in just a few minutes.
Cabaletta Bio, Inc is a biotechnology business based in the US. Cabaletta Bio shares (CABA) are listed on the NASDAQ and all prices are listed in US Dollars. Cabaletta Bio employs 33 staff and has a market cap (total outstanding shares value) of USD$265.4 million.
How to buy shares in Cabaletta Bio
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Cabaletta Bio. Find the stock by name or ticker symbol: CABA. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cabaletta Bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cabaletta Bio, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Cabaletta Bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Cabaletta Bio share price
Use our graph to track the performance of CABA stocks over time.Cabaletta Bio shares at a glance
Information last updated 2021-04-15.
| 52-week range | USD$6.15 - USD$16.38 |
|---|---|
| 50-day moving average | USD$11.2817 |
| 200-day moving average | USD$12.4545 |
| Wall St. target price | USD$22.25 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-0.9376 |
Buy Cabaletta Bio shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cabaletta Bio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cabaletta Bio financials
| Gross profit TTM | USD$0 |
|---|---|
| Return on assets TTM | -16.51% |
| Return on equity TTM | -26.9% |
| Profit margin | 0% |
| Book value | N/A |
| Market capitalisation | USD$265.4 million |
TTM: trailing 12 months
Shorting Cabaletta Bio shares
There are currently 1.7 million Cabaletta Bio shares held short by investors – that's known as Cabaletta Bio's "short interest". This figure is 1.6% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Cabaletta Bio shares can be evaluated.
Cabaletta Bio's "short interest ratio" (SIR)
Cabaletta Bio's "short interest ratio" (SIR) is the quantity of Cabaletta Bio shares currently shorted divided by the average quantity of Cabaletta Bio shares traded daily (recently around 110692.25396825). Cabaletta Bio's SIR currently stands at 15.75. In other words for every 100,000 Cabaletta Bio shares traded daily on the market, roughly 15750 shares are currently held short.
However Cabaletta Bio's short interest can also be evaluated against the total number of Cabaletta Bio shares, or, against the total number of tradable Cabaletta Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cabaletta Bio's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Cabaletta Bio shares in existence, roughly 70 shares are currently held short) or 0.0907% of the tradable shares (for every 100,000 tradable Cabaletta Bio shares, roughly 91 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cabaletta Bio.
Find out more about how you can short Cabaletta Bio stock.
Cabaletta Bio share dividends
We're not expecting Cabaletta Bio to pay a dividend over the next 12 months.
Cabaletta Bio overview
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Frequently asked questions
More guides on Finder
-
How to buy Sigma Labs stock
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
-
How to buy Simpson Manufacturing CoInc stock
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
-
How to buy Sequans Communications S-A stock
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
-
How to buy SFL Corporation stock
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
-
How to buy Senmiao Technology stock
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
-
How to buy Sensata Technologies Holding stock
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
-
How to buy Select Bancorp stock
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
-
How to buy Second Sight Medical Products stock
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
-
How to buy Sibanye Stillwater stock
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
-
How to buy Shinhan Financial Group CoLtd stock
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
Ask an Expert